The EMA published the first summary for the public of the risk-management plan (RMP) of a newly authorized drug. The summary describes what is known and not known about the safety of Mumbai, India-based Piramal Imaging SA’s Neuraceq (florbetaben) and what measures will be taken to prevent or minimize the risks of the radiopharmaceutical used in brain scans.